within Pharmacolibrary.Drugs.ATC.A;

model A07EB01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.01,
    Cl             = 5.28,
    adminDuration  = 600,
    adminMass      = 0.2,
    adminCount     = 1,
    Vd             = 0.00022700000000000002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005766666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Cromoglicic acid, also known as cromolyn sodium, is a mast cell stabilizer used primarily in the treatment and prevention of allergic conditions such as asthma, allergic rhinitis, and allergic conjunctivitis. It reduces allergic symptoms by preventing the release of inflammatory mediators from sensitized mast cells. While once widely used, its use has declined with the advent of newer therapies, but it remains approved in certain formulations and regions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters as reported in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Joyce, P, et al., &amp; Prestidge, CA (2022). Chitosan nanoparticles facilitate improved intestinal permeation and oral pharmacokinetics of the mast cell stabiliser cromoglycate. <i>International journal of pharmaceutics</i> 612 121382–None. DOI:<a href=&quot;https://doi.org/10.1016/j.ijpharm.2021.121382&quot;>10.1016/j.ijpharm.2021.121382</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34919999/&quot;>https://pubmed.ncbi.nlm.nih.gov/34919999</a></p></li><li><p>Zeiss, CR (1992). Intense pharmacotherapy. <i>Chest</i> 101(6 Suppl) 407S–409S. DOI:<a href=&quot;https://doi.org/10.1378/chest.101.6_supplement.407s&quot;>10.1378/chest.101.6_supplement.407s</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1591941/&quot;>https://pubmed.ncbi.nlm.nih.gov/1591941</a></p></li><li><p>Taburet, AM, &amp; Schmit, B (1994). Pharmacokinetic optimisation of asthma treatment. <i>Clinical pharmacokinetics</i> 26(5) 396–418. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199426050-00006&quot;>10.2165/00003088-199426050-00006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7914480/&quot;>https://pubmed.ncbi.nlm.nih.gov/7914480</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A07EB01;
